Novartis Investigative Site

Verona, New Jersey 07044

0 studies enrolling now · 9 studies all time

What they study most

Moderate to Severe Chronic Plaque-Type Psoriasis, Moderate to Severe Chronic Plaque-type Psoriasis, Moderate to Severe Palmoplantar Psoriasis, Moderate to Severe Plaque Psoriasis, Moderate to Severe Plaque-type Psoriasis, Plaque Psoriasis, Psoriasis, Psoriasis, Plaque-type Psoriasis

Studies at this site

• Efficacy and Safety of 2 Secukinumab Regimens in 90kg or More Weight Group With Moderate/Severe Chronic Plaque Psoriasis — Completed
• Study of Efficacy and Safety of Secukinumab 2 mL Auto-injector (300 mg) in Subjects With Moderate to Severe Plaque Psoriasis — Completed
• Investigate Effect of Secukinumab on the PK of Midazolam in Patients With Mod to Sev Plaque Psoriasis — Completed
• Study of Secukinumab With 2 mL Pre-filled Syringes — Completed
• Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis — Completed
• 4 Year Extension Study of Efficacy and Safety of Secukinumab in Patients With Moderate to Severe Chronic Plaque-type Psoriasis — Completed
• Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Palmoplantar Psoriasis — Completed
• Multiple-dose Regimen Study to Assess Effect of 12 Months of Secukinumab Treatment on Skin Response and Biomarkers in Psoriasis Patients — Completed
• Efficacy and Safety of Subcutaneous Secukinumab (AIN457) for Moderate to Severe Chronic Plaque-type Psoriasis Assessing Different Doses and Dose Regimens — Completed